|
|
|
- やすもり しばもと
- 9 years ago
- Views:
Transcription
1 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 11 ) (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I.
2 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb ) (1985) 2), (1990) 3), (2001, 2002) 4 6) CDC ) II. 1. (surgical site infection) (remote infection) 1 5) ) ,8) 1.
3 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 )
4 14( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. CRP ) 4.
5 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 15 ) / 1g 10 5 CFU 5,6) LPS, ) 1) 2) 3) 4) 5) 8. 1) (1)
6 16( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. (2) 2) (1) (2) 1 (3) b - Time above MIC MIC 1 (4) 4 (5) / 3) (1) (2) (3) (4) / 3 (5) (6) ampicillin (ABPC) fosfomycin (FOM) FOM
7 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 17 ) 6. cefotetan (CTT) 4 / FOM b- III. 1. ABPC, piperacillin (PIPC), ampicillin/cloxacillin (ABPC/MCIPC) sulbactam/ampicillin (SBT/ABPC), cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ), cefminox (CMNX) CTT, flomoxef (FMOX), FOM 11 b- FOM 2. 7, 8, 9 MIC
8 18( 18 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 7. MIC (mg/ml)
9 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 19 ) 8. (1)
10 20( 20 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 8.
11 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 21 ) 9.
12 22( 22 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. ABPC ABPC/MCIPC SBT/ABPC ABPC 11 Enterococcus faecalis PIPC Staphylococcus aureus, Staphylococcus epidermidis Enterobacter cloacae Pseudomonas aeruginosa CEZ CTM CMZ FMOX CEZ, CTM Bacteroides fragilis FOM ABPC/MCIPC S. aureus, S. epidermidis, E. faecalis E. cloacae ) CEZ 2.46 CTT 2.58 CMNX 2.48 FOM PIPC 40% ABPC/MCIPC 36.4% 11 FOM 138 CMZ, FMOX, FOM PIPC FOM PIPC, CEZ, CTM, CMZ ABPC CEZ, ABPC/MCIPC, FOM, CMNX 4 2% FOM %, 0.004%, 1 (0.001%) 86)
13 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 23 ) 10.
14 24( 24 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 11.
15 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 25 ) 12.
16 26( 26 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 13.
17 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 27 ) IV. ABPC CEZ CTM FMOX b -
18 28( 28 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1 MRSA 55 75% 87 89) PRSP 50% 90) b- 3 PBP b- b- FOM in vitro in vivo MIC FOM MIC PIPC FOM 91) B. fragilis group PIPC FOM CTT ceftriaxone (CTRX) MRSA MRSA MRSA MRSA V. 3 b - FOM 1) : , ) 94: , 1985
19 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 29 ) 3) 6: , ) , ) 49(S-B): 71 89, ) (1) 18(S-1): , ) MANGRAM, A. J.; T. C. HORAN, M. L. PEARSON, et al.: Guidline for prevention of surgical site infection, Hospital Infection Control Practices Advisory Committee. Infect. Control Hosp. Epidemiol. 20: , ) Prog. Med. 21: , ) Ampicillin 56: , ) Ampicillin Jpn. J. Antibiotics 37: , ) Aminobenzyl Penicillin J. Antibiotics, Ser. B 18: , ) Aminobenzyl-Penicillin Chemotherapy 16: , ) Chemotherapy 36: , ) T-1220 Jpn. J. Antibiotics 30: , ) T-1220 Chemotherapy 25: , ) T-1220 Chemotherapy 25: , ) XIV. Piperacillin Jpn. J. Antibiotics 34: , ) 34: , ) T-1220 Chemotherapy 25: , ) Aminobenzyl Penicillin Methlchloropheylisoxazolyl Penicillin (ViccillinS) 31: , ) Sulbactam Ampicillin Chemotherapy 36(S-8): , ) Sulbactam Ampicillin Chemotherapy 36(S-8): , ) FRANK, U.; E. SCHMIDT-EISENLOHR, A. JOOS-WURTTEMBERGER, et al.: Concentrations of sulbactam/ampicillin in serum and lung tissue. Infection 18: , ) Sulbactam Ampicillin Chemotherapy 36(S-8) , ) Sulbactam Ampicillin Chemotherapy 36(S- 8): , ) Sulbactam Ampicillin, Chemotherapy 36(S-8): , ) Sulbactam/Ampicillin Jpn. J. Antibiotics 42: , ) Sulbactam/Ampicillin Jpn. J. Antibiotics 42: , ) 1g cefazolin 15: , ) Ceftezole Cefazolin Chemotherapy 24: , ) CIMMINO, P. & T. GARACI: Tissue levels of cefazolin in man after parenteral administration. Antibiotica. 11: 31 44, ) COLE, D. R. & J. PUNG: Penetration of cefazolin into pleural fluid. Antimicrob. Agents Chemother. 11: , ) Cefazolin 2,3 Cephalosporin Chemotherapy 22: , ) Cefazolin 43: , ) CEZ CET 29: , ) CEFAZOLIN (CEZ) 39: , ) Cefazolin 14: , ) LIMON, L. L. y; C. A. T. TIRAD, F. FLORES-MERCADO, et al.: Treatment of suppurative otitis media in paediatric patients. J. Int. Med. Res. 3: , 1975
20 30( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 39) Cefotiam (SCE-963) Chemotherapy 27(S-3): , ) Cefotiam Jpn. J. Antibiotics 36: , ) Cefotiam (SCE-963) Chemotherapy 27(S-3): , ) (V) Cefotiam (SCE-963) Chemotherapy 27(S-3): , ) Cefotiam (SCE-963) Chemotherapy 27(S-3): , ) Cefotiam Jpn. J. Antibiotics 35: , ) Cefmetazole 53: 66 74, ), Cefmetazole Jpn. J. Antibiotics 40: , ) CS-1170 Chemotherapy 26(S-5): , ) Cefmetazole Chemotherapy 27: , ) Cefmetazole Chemotherapy 30: , ) CS : , ) 44: , ) CS-1170 Cefazolin 31: , ) Cefmetazole 52: , ) CS-1170 Chemotherapy 26(S- 5): , ) 75: , ) CS-1170 Jpn. J. Antibiotics 32: , ) MT-141 Chemotherapy 32(S-5): , ) MT-141 Chemotherapy 32(S-5): , ) Cefminox Piperacillin Jpn. J. Antibiotics 45: , ) Cefminox Chemotherapy 42: , ) Cefminox Jpn. J. Antibiotics 43: , ) (XXII) MT-141 Chemotherapy 32(S-5): , ) Cefminox 37: , ) Cefminox 36: , ) Cefminox 3: , ) Cephamycin Cefminox Jpn. J. Antibiotics 38: , ) Cefminox Jpn. J. Antibiotics 38: , ) Cefotetan (YM09330) Chemotherapy 30(S-1): , ) Flomoxef. Jpn. J. Antibiotics 41: , ) 6315-S (Flomoxef) Chemotherapy 35(S-1): , ) 6315-S (Flomoxef) RTI Chemotherapy 35(S-1): , ) 6315-S (Flomoxef) Chemotherapy 35(S-1): , ) 6315-S (Flomoxef) Chemotherapy 35(S-1): , ) (XXIX) 6315-S (Flomoxef)
21 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 31 ) Chemotherapy 35(S-1): , ) 6315-S (Flomoxef) ), 6315-S (Flomoxef) Chemotherapy 35(S-1): , ) 6315-S (Flomoxef) ) Fosfomycin Chemotherapy 23: , ) Fosfomycin-Na Jpn. J. Antibiotics 31: , ) Fosfomycin Jpn. J. Antibiotics 35: , ) S 18: , ) Fosfomycin Jpn. J. Antibiotics 37: , ) Fosfomycin sodium Jpn. J. Antibiotics 38: 47 57, ) Fosfomycin sodium Jpn. J. Antibiotics 36: , ) Fosfomycin-Na 29: , ) Fosfomycin sodium 10 prospective 48: , ) MRSA 46: , ) 72: , ) : , ) Streptococcus pneumoniae 51: , ) Fosfomycin Chemotherapy 23: , 1975 ANTIMICROBIAL PROPHYLAXIS IN SURGERY NAGAO SHINAGAWA Department of Surgery, Nagoya Midori Municipal Hospital Antimicrobial prophylaxis is widely performed in any surgical procedures to prevent postoperative infections. However, we have neither double-blind placebo-controlled studies nor sufficient surveillance of postoperative infections that are common in Europe and the United States, and therefore there is little convincing scientific basis accounting for the validity of this therapy. In addition, prophylactic agent is still uncovered by medical insurance despite the persistent arguments as to its necessity. To establish the guidelines in our own country, a greater deal of evidence needs to be accumulated. Strategies for antimicrobial prophylaxis should be determined based on the types of possible postoperative infections and the classifications of operations according to contamination levels in individual operative fields. This process may involve the precise selection of prophylactic agents for suspected contaminating bacterial species in each operative organ and their administration
22 32( 32 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. regimens suitable for the individual surgery. Upon selection of prophylactic agents for postoperative infections, various conditions should be considered: e.g., susceptibility, resistance, blood concentrations, urinary excretion, transition into body fluid and tissues, and adverse reactions. The first and second generations of cephem and cephamycin derivatives can be the first choice, but the use of various other antibacterial agents may be necessary for resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). Cyclic therapy based on penicillins (including mixtures), cephems (including cephamycins) and fosfomycins also seems useful for such resistant strains. At present, there is only limited evidence supporting the importance of prophylactic agents. Controlled trials employing well-designed protocols that endure scientific criticism must be done with due consideration for medical economics.
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun
10 1-14 2014 1 2 3 4 2 1 2 3 4 Web PubMed elbow pain baseball elbow little leaguer s elbow acupuncture electric acupuncture 2003 2012 10 39 32 Web PubMed Key words growth stage elbow pain baseball elbow
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
CHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
東洋医学雑誌
Vol.67 No.2 123-130, 2016 Akiyo GUSHI a Chihaya KORIYAMA b Ryo YOSHINAGA c Hiromi YANO c Junichi TSUMAGARI d Eiichi TAHARA c a Gushi Dermatological Clinic, 45-3 Higashiohsyoji, Satsumasendai city, Kagoshima
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
ABSTRACT The "After War Phenomena" of the Japanese Literature after the War: Has It Really Come to an End? When we consider past theses concerning criticism and arguments about the theme of "Japanese Literature
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
L1 What Can You Blood Type Tell Us? Part 1 Can you guess/ my blood type? Well,/ you re very serious person/ so/ I think/ your blood type is A. Wow!/ G
L1 What Can You Blood Type Tell Us? Part 1 Can you guess/ my blood type? 当ててみて / 私の血液型を Well,/ you re very serious person/ so/ I think/ your blood type is A. えーと / あなたはとっても真面目な人 / だから / 私は ~ と思います / あなたの血液型は
Table 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
840 Geographical Review of Japan 73A-12 835-854 2000 The Mechanism of Household Reproduction in the Fishing Community on Oro Island Masakazu YAMAUCHI (Graduate Student, Tokyo University) This
HPM_442_F_TgCHG_1128
3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med 2004 30 62-7 Guideline Centers for Disease
600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN